x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DPP-001083
| Product Overview | |
|---|---|
| Species | Human |
| Expression System | Baculovirus infected insect cells |
| Format | Liquid |
| Purity | ≥ 95% by SDS-PAGE |
| Nature | Recombinant |
| Target Information | |
|---|---|
| Gene Name | G6PD |
| UniProt No. | P11413 |
| Gene ID | 2539 |
| Molecular Weight | 61 kDa |
| Alternative Names | G6PD; G6PD_HUMAN; G6PD1; G6pdx; Glucose 6 phosphate 1 dehydrogenase; Glucose 6 phosphate dehydrogenase; Glucose 6 phosphate dehydrogenase, G6PD; Glucose-6-phosphate 1-dehydrogenase; MET19; POS10; Zwf1p |
| Function | Catalyzes the rate-limiting step of the oxidative pentose-phosphate pathway, which represents a route for the dissimilation of carbohydrates besides glycolysis. The main function of this enzyme is to provide reducing power (NADPH) and pentose phosphates for fatty acid and nucleic acid synthesis. |
| Involvement In Disease | Anemia, non-spherocytic hemolytic, due to G6PD deficiency |
| Protein Length | Full length protein |
| Sequence | MGSSHHHHHH SSGLVPRGSH MAEQVALSRT QVCGILREEL FQGDAFHQSD THIFIIMGAS GDLAKKKIYP TIWWLFRDGL LPENTFIVGY ARSRLTVADI RKQSEPFFKA TPEEKLKLED FFARNSYVAG QYDDAASYQR LNSHMNALHL GSQANRLFYL ALPPTVYEAV TKNIHESCMS QIGWNRIIVE KPFGRDLQSS DRLSNHISSL FREDQIYRID HYLGKEMVQN LM,Belongs to the glucose-6-phosphate dehydrogenase family. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped on dry ice. |
| Storage | Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
